Literature DB >> 17622769

Phenylacetic acid and arterial vascular properties in patients with chronic kidney disease stage 5 on hemodialysis therapy.

Alexandra Scholze1, Vera Jankowski, Lars Henning, Wiltrud Haass, Antje Wittstock, Sukhbaatar Suvd-Erdene, Walter Zidek, Martin Tepel, Joachim Jankowski.   

Abstract

BACKGROUND: Phenylacetic acid (PAA) is a recently described uremic toxin that inhibits inducible nitric oxide synthase expression and plasma membrane calcium ATPase and may therefore also be involved in remodeling of arteries. Such vascular effects have not been evaluated yet in patients with chronic kidney disease stage 5.
METHOD: We prospectively measured the plasma concentrations of PAA using nuclear magnetic resonance spectroscopy in 50 patients with chronic kidney disease stage 5 (37 men, 13 women) on maintenance hemodialysis. Arterial vascular properties were quantified by the reflective index obtained from digital photoplethysmography.
RESULTS: During the hemodialysis session the plasma PAA concentration was reduced from 3.38 +/- 0.24 mmol/l (mean +/- SEM; median, 2.85 mmol/l; interquartile range, 2.02-4.52 mmol/l) to 2.25 +/- 0.11 mmol/l (median, 2.06 mmol/l; interquartile range, 1.62-2.86 mmol/l; n = 50; p < 0.001). There was a significant correlation between the PAA concentration and the reflective index before the start of the hemodialysis session.
CONCLUSION: The study demonstrates an association of PAA and arterial vascular properties in patients with chronic kidney disease stage 5. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17622769     DOI: 10.1159/000105137

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  6 in total

Review 1.  Normal and pathologic concentrations of uremic toxins.

Authors:  Flore Duranton; Gerald Cohen; Rita De Smet; Mariano Rodriguez; Joachim Jankowski; Raymond Vanholder; Angel Argiles
Journal:  J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 10.121

2.  Effects of end-stage renal disease and dialysis modalities on blood ammonia level.

Authors:  Nosratola D Vaziri; Mahyar Khazaeli; Ane C F Nunes; Kevin T Harley; Hyder Said; Omeed Alipour; Wei Ling Lau; Madeleine V Pahl
Journal:  Hemodial Int       Date:  2016-11-01       Impact factor: 1.812

Review 3.  Cellular and Molecular Mechanisms of Chronic Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its Comorbidities.

Authors:  Prathibha Reddy Gajjala; Maryam Sanati; Joachim Jankowski
Journal:  Front Immunol       Date:  2015-07-08       Impact factor: 7.561

4.  Renal systems biology of patients with systemic inflammatory response syndrome.

Authors:  Ephraim L Tsalik; Laurel K Willig; Brandon J Rice; Jennifer C van Velkinburgh; Robert P Mohney; Jonathan E McDunn; Darrell L Dinwiddie; Neil A Miller; Eric S Mayer; Seth W Glickman; Anja K Jaehne; Robert H Glew; Mohan L Sopori; Ronny M Otero; Kevin S Harrod; Charles B Cairns; Vance G Fowler; Emanuel P Rivers; Christopher W Woods; Stephen F Kingsmore; Raymond J Langley
Journal:  Kidney Int       Date:  2015-05-20       Impact factor: 10.612

5.  Lack of influence of serum magnesium levels on overall mortality and cardiovascular outcomes in patients with advanced chronic kidney disease.

Authors:  Olimpia Ortega; Isabel Rodriguez; Gabriela Cobo; Julie Hinostroza; Paloma Gallar; Carmen Mon; Milagros Ortiz; Juan Carlos Herrero; Cristina Di Gioia; Aniana Oliet; Ana Vigil
Journal:  ISRN Nephrol       Date:  2013-06-19

6.  Salivary metabolites associated with a 5-year tooth loss identified in a population-based setting.

Authors:  Maik Pietzner; Thomas Kocher; Leonie Andörfer; Birte Holtfreter; Stefan Weiss; Rutger Matthes; Vinay Pitchika; Carsten Oliver Schmidt; Stefanie Samietz; Gabi Kastenmüller; Matthias Nauck; Uwe Völker; Henry Völzke; Laszlo N Csonka; Karsten Suhre
Journal:  BMC Med       Date:  2021-07-14       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.